COVID-19 and investments will shape the outsourcing industry for the near term.

CMOs and CDMOs: Pandemic and Beyond

Advances in technology are accelerating the development and manufacture of subunit vaccines.

Subunit Vaccines and the Fight Against COVID-19

Topic

Hallie Forcinio is packing editor for Pharmaceutical Technology and Pharmaceutical Technology Europe, editorhal@sbcglobal.net.

Articles

Protective external packaging ensures COVID-19 vaccines arrive safely. 

Sustainable Shippers for Ultra-Cold Conditions

FDA amended it’s Emergency Use Authorization to shorten Moderna’s vaccine  booster dose interval from six to five months.

FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine

Intravacc is partnering with Leiden University Medical Center for the development and evaluation of a new intranasal coronavirus vaccine candidate in a clinical Phase I/II study. 

Clinical Trial on Intranasal Coronavirus Vaccine Set to Start

The agency is expanding the use of a single booster of the Pfizer-BioNTech vaccine to children ages 12–15 and is shortening the time between primary vaccination and booster to at least five months.  

FDA Expands Use of Pfizer-BioNTech COVID-19 Vaccine

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

FDA authorized emergency use of Pfizer’s oral antiviral drug to make the drug available as quickly as possible. 

Here Come the COVID-19 Treatment Options

Moderna’s vaccine is weaker against the Omicron variant, but boosters can increase neutralizing antibody levels by as much as 83-fold.

Moderna Releases New Vaccine Data Concerning Omicron Variant

The agency recommended granting conditional marketing authorization for use of Nuvaxovid in people 18 years of age and older.

EMA Recommends Conditional Authorization for Novavax’s COVID-19 Vaccine

GlaxoSmithKline and Vir Biotechnology have received a conditional marketing authorization from MHRA for Xevudy (sotrovimab) in the treatment of COVID-19.

GSK and Vir Biotechnology’s Xevudy Gets Conditional Marketing Authorization from MHRA for COVID-19 Treatment

Moderna’s agreement with the UK government includes 29 million COVID-19 vaccine doses for delivery in 2022 and 31 million doses for delivery in 2023.

60 Million Doses of the COVID-19 Vaccine is Added to Moderna’s Supply Agreement with the UK

Rasmus Kidmose is European Business Development director at CRB.

Eric Unrau is vice-president of Operations, Europe, at CRB.

Can Aktar is leader of the Basel office, at CRB

Lean delivery offers a promising solution to supply and manufacturing bottlenecks by integrating project teams early on and widening the team’s field of view.

COVID-19 Update

CMOs and CDMOs: Pandemic and Beyond

Subunit Vaccines and the Fight Against COVID-19